Epithalon

Epithalon (Epitalon; Ala-Glu-Asp-Gly) is a synthetic tetrapeptide isolated as the active component of epithalamin, the crude bovine pineal polypeptide extract. In 2017 the identical AEDG sequence was confirmed to occur endogenously in human pineal tissue. Development is attributed to Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, with a research programme spanning more than 35 years, almost entirely from a single group and without independent Western replication.

Two described targets. First, telomerase: the enzyme is transcriptionally silenced in most adult somatic cells, so telomeric attrition with each division proceeds unopposed until replicative senescence or apoptosis, with senescent cells then secreting inflammatory mediators. Epithalon is small enough to enter the nucleus and reactivates telomerase expression in telomerase-negative cells. Second, the pineal gland: age-related calcification reduces melatonin output by roughly 50% by age 60 and flattens the circadian amplitude. Epithalon restores melatonin secretion towards youthful patterns in aged subjects while having minimal effect in young subjects with normal function.

The framing is characteristic of the bioregulator class, with actions described at the level of gene expression and chromatin rather than receptor signalling. Earlier site material also named suppression of the genes written as CCI11 and HMGH1, spellings reproduced as printed.

A critical distinction: the clinical trials that produced the mortality data used epithalamin at 5 to 10 mg per day, whereas the synthetic peptide matched its effects in primates at 10 mcg per day, a 500 to 1000 fold potency difference. The widely repeated milligram protocols therefore derive from the crude extract, not from the compound actually sold.

Presentation is lyophilised powder, typically 10 mg vials (50 mg vials also exist). Route is subcutaneous injection in the evening on short cycles repeated two to three times per year. It is not FDA approved and is not scheduled or banned by WADA as of early 2026.

Telomerase activation. The primary mechanism. A 2003 study in Bulletin of Experimental Biology and Medicine (Khavinson et al.) showed increased expression of the telomerase catalytic subunit, upregulated telomerase activity, and a 33% extension of telomere length in previously telomerase-negative human fetal fibroblasts, which continued dividing beyond passage 34. Al-Dulaimi et al. (Biogerontology, 2025) confirmed dose-dependent telomere extension via hTERT mRNA upregulation and increased telomerase activity in normal HMEC epithelial and IBR.3 fibroblast cells. In breast cancer lines (21NT, BT474) extension occurred instead through the Alternative Lengthening of Telomeres (ALT) pathway, with only minor ALT activity in normal cells.

Pineal stimulation. Epithalon restores pineal melatonin secretion in aged organisms. Studies in aged monkeys and elderly humans normalised the circadian melatonin production pattern (Korkushko et al., 2004). Melatonin acts antiphase to cortisol and gates nocturnal growth hormone pulsatility, tissue repair, and immune activation; age-related pineal calcification reduces output by roughly 50% by age 60 and blunts the amplitude of the rhythm. Effects in young subjects with intact function are minimal, consistent with restoration rather than supraphysiological drive.

Epigenetic regulation. Epithalon binds promoter regions and alters chromatin structure, inducing decondensation of pericentromeric heterochromatin in cells from elderly individuals (Khavinson et al., 2003, Neuroendocrinol Lett), increasing transcriptional accessibility. Earlier material also described stimulation of DNA repair, including protection against radiation-induced damage, and suppression of the genes written as CCI11 and HMGH1.

Antioxidant enzyme induction. Increased superoxide dismutase, glutathione peroxidase, and glutathione S-transferase activity in animal models; a 2025 review found epithalamin required roughly 1000 fold higher doses than Epithalon to match antioxidant effects.

Immune modulation. Modulation of cytokine expression and T cell function in aged animals.

Telomere and senescence: telomerase reactivation with telomere elongation in vitro (33%, 2003) and significantly increased leukocyte telomere length in humans aged 60 to 80, comparable between Epithalon and epithalamin. Delayed replicative senescence; stimulation of DNA repair including radiation protection.

Mortality: the 12-year cardiovascular study followed 79 patients receiving intramuscular epithalamin in short cycles twice yearly for 3 years then 9 further years of follow-up, giving 28% lower all-cause mortality and cardiovascular mortality halved, with improved endurance, normalised melatonin rhythm, and better metabolic markers. The 266-patient longevity study (Khavinson and Morozov, 2003) treated elderly adults for 2 to 3 years with 6 to 8 years of follow-up: 1.6 to 1.8 fold mortality reduction, 2.5 fold when combined with Thymalin, and 4.1 fold in a group treated annually for 6 years.

Lifespan and oncology: 12 to 17% lifespan extension in mice (Anisimov et al.), with reduced spontaneous tumour incidence and fewer metastases in female C3H/He mice. Earlier material describes inhibition of carcinogenic receptor expression with anti-tumour effect in breast and colorectal cancer and activity against hormone-dependent tumours, and adoption by the Russian medical industry for tumour inhibition. The ALT-pathway finding in breast cancer lines (2025) is noted as an unresolved question.

Neuroendocrine: restoration of pineal melatonin secretion and circadian normalisation in aged monkeys and elderly humans; 1.6 fold increase in melatonin synthesis versus placebo with sublingual 500 mcg per day for 20 days, with measurable circadian gene expression changes.

CNS: improved retention and recall; neuronal protection; increased dendritic spines and branching; possible effect on anxiety, depression, and emotional regulation.

Inflammatory and oxidative: cytokine and C-reactive protein regulation with stated relevance to rheumatoid arthritis and ulcerative colitis; antioxidant enzyme induction and suppression of oxidative stress markers; immune modulation via T cell function.

Other: treatment of anovulatory infertility of hormonal origin; normalisation of apoptotic timing; positive clinical effect in 90% of 162 retinitis pigmentosa patients with no reported side effects.

Epithalon activates and resets cellular processes rather than maintaining a pharmacological level, and effects persist for months after clearance. Research on continuous dosing showed no additional benefit over periodic cycles, which is the rationale for short courses.

Timeline: sleep effects are the earliest and most consistently reported, typically within 1 to 2 weeks, with deeper sleep and improved morning restoration. Vivid dreams are frequent, particularly in the first week, and transient sleep pattern changes, drowsiness, mild fatigue, or mild headache may occur early in a cycle. Injection site reactions typically resolve within three days. Users report improved recovery and energy less consistently, probably secondary to sleep.

Telomere effects are imperceptible; the human mortality data emerged over 6 to 12 years of follow-up. No acute subjective signal should be expected from that arm of the pharmacology.

Responders: adults 35 and older with age-related decline in sleep quality and recovery. In young subjects with intact pineal function the effect is minimal, consistent with restoration rather than augmentation.

Lifestyle constraints apply: evening light exposure and sustained evening cortisol elevation counteract the melatonin mechanism, and the trials enrolled subjects whose systems had declined with age rather than those with lifestyle-driven disruption.

Evidence caveat: nearly all published work comes from the Khavinson group, without independent Western replication. A 2025 review also noted that formal safety data remains limited.

Dose selection turns on the epithalamin versus Epithalon distinction. The trials generating the mortality data used the crude bovine pineal extract at 5 to 10 mg per day. The synthetic tetrapeptide, in the direct primate comparison, produced the same melatonin restoration at 10 mcg per animal per day against 5 mg for epithalamin, a 500 fold difference, and a 2025 review put the potency gap for antioxidant effects at roughly 1000 fold. The widely circulated 5 to 10 mg daily protocols, and the schedule of 10 mg on days 1, 5, 9, 13, and 17 previously listed on this page, therefore derive from extract dosing rather than from data on the compound actually being administered.

Studied synthetic doses: 10 mcg per day (primate) and 500 mcg per day sublingually for 20 days (human circadian trial, 1.6 fold melatonin increase).

Practical protocol: 500 mcg to 1 mg once daily, subcutaneous, in the evening to align with the melatonin mechanism, for 10 to 20 consecutive days per cycle, 2 to 3 cycles per year with several months between. Continuous dosing showed no additional benefit over periodic cycling; the model is activation followed by endogenous maintenance, then reinforcement.

Reconstitution, 10 mg vial: 2 mL bacteriostatic water gives 5 mg/mL, 50 mcg per insulin unit. Check: 500 mcg = 10 units; 1 mg = 20 units.

The previously listed protocols reconstituted 10 mg vials in 1 mL (10 mg/mL) or 3 mL (3.33 mg/mL) and 50 mg vials in 3 mL (16.67 mg/mL), for doses of 100 mcg to 10 mg per day. Those unit calculations were internally consistent but the milligram doses are one to two orders of magnitude above the synthetic-peptide evidence. Food-independent timing. Endogenous melatonin elevation compounds with exogenous melatonin.

The evidence base spans over 35 years but derives almost entirely from the St. Petersburg Institute of Bioregulation and Gerontology group under Khavinson, with no independent Western replication. Follow-up durations are unusually long; single-group provenance is the principal limitation.

In vitro. Bulletin of Experimental Biology and Medicine, 2003: human fetal fibroblasts showed increased expression of the telomerase catalytic subunit, upregulated telomerase activity, 33% telomere elongation in previously telomerase-negative cells, and division beyond passage 34 with preserved function. Biogerontology, 2025 (Al-Dulaimi and colleagues): dose-dependent telomere extension in HMEC and IBR.3 cells via hTERT mRNA upregulation and increased telomerase activity; in 21NT and BT474 breast cancer lines extension occurred through the Alternative Lengthening of Telomeres (ALT) pathway, with only minor ALT activity in normal cells. Chromatin work (Neuroendocrinology Letters, 2003) reports heterochromatin decondensation near centromeres in cells from elderly donors.

Human. Telomere lengthening in blood cells of subjects aged 60 to 80, comparable between Epithalon and Epithalamin. 12-year cardiovascular study: 79 patients, intramuscular Epithalamin in short cycles twice yearly for 3 years plus 9 years follow-up; 28% lower all-cause mortality, cardiovascular mortality halved, improved endurance, normalised melatonin rhythm, improved metabolic markers. 266-patient longevity study: 2 to 3 years treatment, 6 to 8 years follow-up, 1.6 to 1.8 fold mortality reduction; 2.5 fold with Thymalin; 4.1 fold in a group treated annually for 6 years. Bulletin of Experimental Biology and Medicine, 2004: normalised circadian melatonin pattern in elderly subjects. Sublingual Epithalon 500 mcg per day for 20 days: 1.6 fold melatonin synthesis increase versus placebo with circadian gene expression changes. Retinitis pigmentosa: 162 patients, positive effect in 90%, no reported side effects.

Potency. Primate study, 2003: Epithalamin 5 mg per animal per day and Epithalon 10 mcg per animal per day produced equivalent melatonin restoration — a 500 fold difference. A 2025 review reports roughly 1000 fold higher Epithalamin doses required to match antioxidant effects. Effects in young subjects with normal function were minimal.

Animal. Anisimov and colleagues: 12 to 17% lifespan extension in mice; reduced spontaneous tumour incidence and fewer metastases in female C3H/He mice; increased superoxide dismutase, glutathione peroxidase, and glutathione S-transferase activity.